Decitabine improves response rate and prolongs progression‐free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO‐016 trial

REFERENCES [1] Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–492. https://doi.org/10.1016/j. mayocp.2013.12.012. [2] Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–1675. https://doi.org/10.1182/blood-2015-12-684399. [3] Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60– 71. https://doi.org/10.1182/blood-2016-02-700013. [4] Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19): 1533–1536. https://doi.org/10.1182/bloodadvances.2017007526. [5] Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther. In press. https://doi.org/10.1016/j.hemonc.2017.07.002. [6] Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol. 2018;93: E47–E49. https://doi.org/10.1002/ajh.24971. [7] Jordan MB, Allen CE, Weitzman S, Filipovich AH, Mcclain KL. How I treat How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–4052. https://doi.org/10.1182/blood-2011-03278127.